Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus MICAFUNGIN IN SODIUM CHLORIDE 0 9.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus MICAFUNGIN IN SODIUM CHLORIDE 0 9.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs MICAFUNGIN IN SODIUM CHLORIDE 0.9%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Micafungin is an echinocandin antifungal that inhibits the synthesis of 1,3-beta-D-glucan, an essential component of the fungal cell wall, leading to osmotic instability and cell death.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
100 mg intravenously once daily for invasive candidiasis; 150 mg intravenously once daily for esophageal candidiasis.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Terminal elimination half-life is approximately 13-20 hours in adults; supports once-daily dosing. Half-life is prolonged in moderate-to-severe hepatic impairment (Child-Pugh B/C) but no dosage adjustment is required.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Primarily biliary/fecal (≈71% of administered dose recovered in feces as parent drug and metabolites); renal excretion accounts for ≈15% (urine: <1% as unchanged drug).
Category C
Category A/B
Electrolyte
Electrolyte